You are here
Apellis Pharmaceuticals to Host R&D Day on June 26, 2018
CRESTWOOD, Ky. and CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it will host an R&D Day from 2:00 p.m. to 5:00 p.m. Eastern Time on June 26, 2018 in New York City.
Apellis’ senior executive team will be joined by leading clinicians and researchers to provide an overview of the Company’s clinical programs for APL-2 in geographic atrophy and paroxysmal nocturnal hemoglobinuria, as well as its early-stage pipeline.
The R&D Day will feature presentations from the following external experts:
- Usha Chakravarthy, MD, PhD, Professor of Ophthalmology and Consultant Ophthalmic Surgeon, Queen’s University of Belfast
- Jeffrey S. Heier, MD, Co-President and Medical Director, Ophthalmic Consultants of Boston
- Jason S. Slakter, MD, Clinical Professor of Ophthalmology, NYU School of Medicine and Director, Digital Angiography Reading Center
- Peter Hillmen, MD, PhD, Professor of Experimental Haematology, University of Leeds
- Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Consultant Haematologist and Lead Clinician for the National PNH Service, UK
- Richard Glassock, MD, MACP, Professor Emeritus, David Geffen School of Medicine at UCLA and Founding Editor-in-Chief, ASN NephSAP Journal
The live webcast and slide presentation may be accessed by visiting the “Events and Presentations” page of the “Investors and Media” section of the Company’s website at http://www.apellis.com. Replay of the webcast will be available for 90 days following the event.
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds for the treatment of a broad range of life-threatening or debilitating autoimmune diseases based upon complement immunotherapy through the inhibition of the complement system at the level of C3. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. For additional information about Apellis and APL-2, please visit http://www.apellis.com.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials such as the results referenced in this release will be indicative of results that will be generated in future clinical trials; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of such clinical trials will warrant regulatory submission; whether APL-2 will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; whether Apellis’ cash resources will be sufficient to fund the company's foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on April 30, 2018, and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT: Investor Contact: Alex Kane firstname.lastname@example.org 212.301.7218 (office) 929.400.2691 (mobile) Media Contact: Tully Nicholas email@example.com 617.482.0042 (office) 860.490.0218 (mobile)